New drug discovery: Extraordinary opportunities in an uncertain time

Drug Discovery Today

Volumn 20, Issue 11, 2015, Pages 1288-1292

  Kinch, Michael S ^a   Flath, Richard ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b Institute for Life Sciences Collaboration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG RESEARCH; HUMAN; MERGERS AND ACQUISITIONS; ORGANIZATION AND MANAGEMENT; POLYPHARMACOLOGY; PROGRAM SUSTAINABILITY; REVIEW; UNCERTAINTY; DRUG DESIGN; DRUG DEVELOPMENT; NONBIOLOGICAL MODEL; PROCEDURES; PUBLIC HEALTH;

DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, ORGANIZATIONAL; PRIVATE SECTOR; PUBLIC HEALTH; PUBLIC SECTOR;

EID: 84947024020     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.12.008     Document Type: Short Survey

References (20)

1. F.S. Collins Reengineering translational science: the time is right Sci. Transl. Med. 3 2011 90cm17
2. M. Mazzucato The entrepreneurial state Soundings 49 2011 131 142
3. K.R. Matherlee The outlook for clinical research: impacts of federal funding restraint and private sector reconfiguration Acad. Med. 70 1995 1065 1072
4. A.J. Stevens, and et al. The role of public-sector research in the discovery of drugs and vaccines N. Eng. J. Med. 364 2011 535 541
5. BankBoston (1997) MIT: the impact of innovation. A BankBoston economics department special report, http://www.saveourheritage.com/Library-Docs/Bank%20Boston%20Impact%20of%20Innovation.pdf
6. M.R. Trusheim, and E.R. Berndt Economic challenges and possible policy actions to advance stratified medicine Personal. Med. 9 2012 413 427
7. O. Wellman-Labadie, and Y. Zhou The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95 2010 216 228
8. M. Wastfelt, and et al. A journey of hope: lessons learned from studies on rare diseases and orphan drugs J. Int. Med. 260 2006 1 10
9. T.F. Schäberle, and I.M. Hack Overcoming the current deadlock in antibiotic research Trends Microbiol. 22 2014 165 167
10. Infectious Diseases Society of America Combating antimicrobial resistance: policy recommendations to save lives Clin. Infect. Dis. 52 2011 S397 S428
11. Infectious Diseases Society of America The 10 × ′20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 Clin. Infect. Dis. 50 2010 1081 1083
12. M.A. Cooper, and D. Shlaes Fix the antibiotics pipeline Nature 472 2011 32
13. M.S. Kinch, and et al. Trends in pharmaceutical targeting of clinical indications: 1930-2013 Drug Discov. Today 19 2014 1682 1685
14. B. Pekarsky Should financial incentives be used to differentially reward 'me-too' and innovative drugs? PharmacoEconomics 28 2010 1 17
15. K. Outterson, and et al. Approval and withdrawal of new antibiotics and other antiinfectives in the US 1980-2009 J. Law Med. Ethics 41 2013 688 696
16. E.R. Berndt, and et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness Health Econ. 16 2007 491 511
17. O. Barder, and et al. Advance market commitments: a policy to stimulate investment in vaccines for neglected diseases Econ. Voice 2006 2006 3
18. K. Lustig, and et al. The evolution of the contract research organisation and the future of the pharmaceutical industry Eur. Pharm. Rev. 18 2013 60 62
19. V. Wadhwa A reverse brain drain Issues Sci. Technol. 25 2009 45 52
20. D. Zweig Competing for talent: China's strategies to reverse the brain drain Int. Labour Rev. 145 2006 65 90